• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

RCT Results: Can Semaglutide Lead to Weight Reduction in Individuals Who are Not Diabetic?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Semaglutide is an approved treatment for type 2 diabetes and reduces the risk of cardiovascular events in this population
  • Wilding et al. (NEJM, 2021) examined whether adults with obesity can achieve weight loss with this medication, along with lifestyle intervention

METHODS:

  • Randomized, double-blind, placebo-controlled trial
  • Participants
    • BMI ≥30 or ≥27 (in addition to ≥1 weight-related coexisting condition)
    • Non-diabetic
  • Interventions (randomized 2:1)
    • Semaglutide and lifestyle intervention | 68 weeks of treatment with once-weekly subcutaneous semaglutide 2.4 mg
    • Placebo and lifestyle intervention
  • Primary outcomes
    • Percentage change in body weight
    • Weight reduction of at least 5%

RESULTS:

  • 1306 participants in semaglutide | 655 participants in placebo
  • Participants in the semaglutide group experienced a significantly greater change in body weight from baseline to week 68 (P < 0.001)
    • Semaglutide: −14.9%
    • Placebo: −2.4%
    • Estimated treatment difference: −12.4 percentage points (95% CI, −13.4 to −11.5)
  • More participants in the semaglutide group achieved weight reduction at 68 weeks
    • 5% or more
      • Semaglutide: 86.4%
      • Placebo: 31.5%
    • 10% or more
      • Semaglutide: 69.1%
      • Placebo: 12.0%
    • 15% or more
      • Semaglutide: 50.5%
      • Placebo: 4.9%
    • P <0.001 for all three comparisons of odds
  • Change in body weight from baseline to week 68
    • Semaglutide: −15.3 kg
    • Placebo: −2.6 kg
    • Estimated treatment difference: −12.7 kg (95% CI, −13.7 to −11.7)
  • Participants who received semaglutide had
    • Greater improvement with respect to cardiometabolic risk factors
    • Greater increase in participant-reported physical functioning from baseline
  • Side effects of Semaglutide
    • Primarily nausea and diarrhea
    • Typically transient and mild-to-moderate in severity and subsided with time
    • More participants in the semaglutide group discontinued treatment owing to GI events vs placebo (4.5% vs 0.8%)

CONCLUSION:

  • Semaglutide plus lifestyle interventions resulted in sustained weight loss in non-diabetic individuals
  •  The authors conclude

…that among adults with overweight or obesity (without diabetes), once-weekly subcutaneous semaglutide plus lifestyle intervention was associated with substantial, sustained, clinically relevant mean weight loss of 14.9%, with 86% of participants attaining at least 5% weight loss 

Learn More – Primary Sources:

Once-Weekly Semaglutide in Adults with Overweight or Obesity

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Can Online Weight Management Programs Combined with Nonclinical Staff Support Help Achieve Weight Loss?
RCT Results: Does Intermittent Fasting Improve Weight Loss for Those with Overweight or Obesity?
Results from the TEMPO Diet Trial: What are the Long-term Effects of Severe Energy-Restriction for Women with Postmenopausal Obesity?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site